Correlation between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma

American Journal of Clinical Pathology

Volumn 142, Issue 3, 2014, Pages 391-397

  Mano, Yohei ^a   Aishima, Shinichi ^a   Kubo, Yuichiro ^a   Tanaka, Yuki ^a   Motomura, Takashi ^a   Toshima, Takeo ^a   Shirabe, Ken ^a   Baba, Shingo ^a   Maehara, Yoshihiko ^a   Oda, Yoshinao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

FDG positron emission tomography; GLUT1; Hepatocellular carcinoma; HIF1 ; STAT3

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SODIUM GLUCOSE COTRANSPORTER 1; STAT3 PROTEIN; DIAGNOSTIC AGENT; GLUCOSE TRANSPORTER 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SIZE; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; TUMOR INVASION; FDG POSITRON EMISSION TOMOGRAPHY; HIF1Α; LIVER TUMOR; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; SCINTISCANNING; VERY ELDERLY;

FDG POSITRON EMISSION TOMOGRAPHY; GLUT1; HEPATOCELLULAR CARCINOMA; HIF1Α; STAT3;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84907178632     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPG8AFJ5NRKLLM     Document Type: Article

References (38)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
2. Shirabe K, Kanematsu T, Matumata T, et al. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univari ate and multivariate analyses. Hepatology. 1991;14:802-805.
3. Taura K, Ikai I, Hatano E, et al. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival o f patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244:265-273.
4. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
5. Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluor ine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30:1736-1741.
6. Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluor odeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427-433.
7. Medina RA, Owen G I. Glucose transporters: expression, regulation and cancer. Biol Res. 2002;35:9-26.
8. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39:1727-1735.
9. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose tr ansporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
10. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98:295-303.
11. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18:254-267.
12. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178:2623-2629.
13. Berishaj M, Gao SP, Ahmed S, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/gl ycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007;9:R32.
14. Lin Q, Lai R, Chirieac LR, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005;167:969-980.
15. Song L, Turkson J, Karras JG, et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003;22:4150-4165.
16. Greten FR, Weber CK, Greten TF, et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology. 2002;123:2052-2063.
17. Ni Z, Lou W, Leman ES, et al. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000;60:1225-1228.
18. Kreis S, Munz GA, Haan S, et al. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res. 2007;5:1331-1341.
19. Rajendran P, Ong TH, Chen L, et al. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res. 2011;17:1425-1439.
20. Yang SF, Wang SN, Wu CF, et al. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol. 2007;60:642-648.
21. Ogata H, Kobayashi T, Chinen T, et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology. 2006;131:179-193.
22. Mano Y, Aishima S, Fujita N, et al. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology. 2013;80:146-154.
23. Demaria M, Giorgi C, Lebiedzinska M, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY). 2010;2:823-842.
24. Chen C, Pore N, Behrooz A, et al. Regulation of glut1 mRNA by hypoxia-inducible factor-1: interaction between H-ras and hypoxia. J Biol Chem. 2001;276:9519-9525.
25. Kitamura K, Hatano E, Higashi T, et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol. 2011;55:846-857.
26. Liver Cancer Study Group of Japan. General R ules for the Clinical and Pathological Study of Primary Liver Cancer. 2nd ed. Tokyo, Japan: Kanehara; 2003.
27. Maeda T, Adachi E, Kajiyama K, et al. Spindle cell hepatocellular carcinoma: a clinicopathologic and immunohistochemical analysis of 15 cases. Cancer. 1996;77:51-57.
28. Kaelin WG Jr., Thompson CB. Q&A: Cancer: clues from cell metabolism. Nature. 2010;465:562-564.
29. Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase sign aling in colon cancer cells. J Biol Chem. 2002;277:38205-38211.
30. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005;24:5552-5560.
31. Niu G, Briggs J, Deng J, et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression i n both tum-or cells and tumor-associated myeloid cells. Mol Cancer Res. 2008;6:1099-1105.
32. Wada H, Nagano H, Yamamoto H, et al. Expression pattern of angiogenic factors and prognosis after hep atic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 2006;26:414-423.
33. Heilig CW, Liu Y, England RL, et al. D-glucose stimula tes mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes. 1997;46:1030-1039.
34. Schwartzenberg-Bar-Yoseph F, Ar moni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004;64:2627-2633.
35. Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105:659-669.
36. Fillies T, Werkmeister R, van Diest PJ, et al. HIF1-alpha overexpression indica tes a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer. 2005;5:84.
37. Godoy A, Ulloa V, Rodr íguez F, et al. Differential subcellular distribution of glucose t ransporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol. 2006;207:614-627.
38. Paudyal B, Paudyal P, Oriuchi N, et al. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol. 2008;33:1047-1054.